Table 2.
Clinical outcomes for Fanconi anemia mosaic patients
| A. Mosaic with blood count normalization (n = 37) | |||
|---|---|---|---|
| Status | n (%) | Age (y) | |
| Alive at last follow-up | 34 (92%) | At last follow-up: | Median: 18 Range: 4–34 |
| Deceased at follow-up | 3 (9%) | At death: | 19, 29, 29 |
| BMF | 1 (3%) | At BMF diagnosis: | 20 |
| AML/MDS | 1 (3%) | At AML/MDS diagnosis: | 19 |
| Solid organ malignancy | 4 (11%) | At cancer diagnosis: | Median: 29 Range: 24–33 |
| B. Mosaic with no/incomplete blood count normalization (n = 15) | |||
| Status | n (%) | Age (y) | |
| Alive at last follow-up | 8 (53%) | At last follow-up: | Median:14 Range: 8–47.5 |
| Deceased at follow-up | 7 (47%) | At death: | Range: 9–39 |
| BMF | 12 (80%) | At BMF diagnosis: | Median: 9.5 Range: 0–47.5 |
| AML/MDS | 2 (13%) | At AML/MDS diagnosis: | 17.5, 47.5 |
| Solid organ malignancy | 2 (13%) | At cancer diagnosis: | 38, 39 |